Non interventionel prospective study to develop a prognostic scoring system for outcome of autologous transplantation in multiple myeloma (MM).

Non interventionel prospective study to develop a prognostic scoring system for outcome of autologous transplantation in multiple myeloma (MM). - EBMT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003964

Enrollment

Registered

2015-05-12

Start date

2012-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90 C90

Interventions

Group 1: The study aims to prospectively audit autcomes of autologous stem cell transplantations for Multiple Myeloma and validate the use of a prognostic score. Data on tumour load at diagnosis will

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: MM-patients.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The aim o the study is to prospectively validate a prognostic scoring sytem for outcomes (EFS,OS) of autologous transplantation in Multiple Myeloma, developed retrospectively at Hammersmith Hospital, London, based on tumour load at diagnosis (Plasmacell% on trephine),cytogenetic aberrations (FISH and metaphase cytogenetics) and treatment responses to chemotherapy prior to autologous transplant.	—

Secondary

Measure	Time frame
Test the predictive power of the score to identify a subgroup of high risk patients who currently profit least from autologous stem cell transplantion and may be candidates for therapeutic trials of novel agents. Develop the prognostic score as a tool for such risk adapted therapies. Validate the scoring sytem in patients treated with novel agents/drug combinations Further definition of cytogenetic risk groups	—

Measure

Time frame

Test the predictive power of the score to identify a subgroup of high risk patients who currently profit least from autologous stem cell transplantion and may be candidates for therapeutic trials of novel agents. Develop the prognostic score as a tool for such risk adapted therapies. Validate the scoring sytem in patients treated with novel agents/drug combinations Further definition of cytogenetic risk groups

—

Countries

Germany, Netherlands

Contacts

Public ContactMonika Engelhardt

Universitätsklinikum Freiburg

monika.engelhardt@uniklinik-freiburg.de+49 761 270 32460

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026